{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:13:17Z","timestamp":1793945597970,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clinthera.2023.11.014","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T18:07:42Z","timestamp":1702577262000},"page":"134-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Ekaterina","family":"Proskuriakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-083X","authenticated-orcid":false,"given":"Dhan Bahadur","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Jasaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Ketan","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Shtembari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Gaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramjeet","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kadariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.11.014_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fimmu.2020.00045","article-title":"Editorial: BCR Signaling and B Cell Activation","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0002","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2016-09-693598","article-title":"How I manage ibrutinib-refractory chronic lymphocytic leukemia","volume":"129","author":"Woyach","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0003","unstructured":"Taking IMBRUVICA\u00ae (ibrutinib). Pharmacyclics. Accessed September 18, 2023. https:\/\/www.imbruvica.com\/taking-imbruvica?utm_source=google&utm_medium=cpc&utm_campaign=GO-USA-ENG-PS-Imbruvica-BC-PH-RN-DTC_Core&utm_content=Package+Insert&utm_term=imbruvica+package+insert&gclid=Cj0KCQjwx5qoBhDyARIsAPbMagCaiunEBcWuxylE6L2KlW1_mVuKDqScRtVUe24zH8Nw13htCclP8agaAu28EALw_wcB&gclsrc=aw.ds."},{"key":"10.1016\/j.clinthera.2023.11.014_bib0004","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances","volume":"35","author":"Wen","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-021-00467-7","article-title":"Ibrutinib combinations in CLL therapy: scientific rationale and clinical results","volume":"11","author":"Timofeeva","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0006","unstructured":"Patient support programs. CALQUENCE\u00ae (acalabrutinib) 100 mg tablets. AstraZeneca. Accessed September 18, 2023. https:\/\/www.calquencehcp.com\/support-and-resources\/patient-support.html?source=cqe_m_h_3&umedium=cpc&uadpub=google&ucampaign=calquencehcpbranded_cll_generic_supportandresources_2020_hcp&ucreative=brandedgenericpackageinsertagnostic_ph&uplace=acalabrutinibpackageinsert&outcome=hcp&cmpid=1&gclid=Cj0KCQjwx5qoBhDyARIsAPbMagDctH9EjmclnFEoB7gxjhSboyFPmoWbyBH1b9BW8a0uhFKmTNMM-QkaAu7-EALw_wcB&gclsrc=aw.ds."},{"key":"10.1016\/j.clinthera.2023.11.014_bib0007","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0009","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development","volume":"61","author":"Crawford","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0010","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1002\/eji.1830241228","article-title":"Expression of Bruton's tyrosine kinase protein within the B cell lineage","volume":"24","author":"Genevier","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0011","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/cells10061270","article-title":"Mast Cells: A New Frontier for Cancer Immunotherapy","volume":"10","author":"Lichterman","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0012","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0013","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0014","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0015","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood.2022017791","article-title":"Cardiotoxicity in patients treated with acalabrutinib","volume":"140","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2023.11.014_bib0016","doi-asserted-by":"crossref","first-page":"9882","DOI":"10.1182\/blood-2022-168152","article-title":"Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0017","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0018","unstructured":"Proskuriakova E, Gaire S, Shrestha D, Raut A. Cardiovascular adverse events associated with Second generation Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy, Acalabrutinib and Zanubrutinib: A systematic review and Meta-analysis. PROSPERO: International prospective register of systematic reviews. 2023. CRD42023392406. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=392406. Accessed February 3, 2023."},{"key":"10.1016\/j.clinthera.2023.11.014_bib0019","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0020","unstructured":"9.5.2 Identifying and measuring heterogeneity. Accessed February 3, 2023. https:\/\/handbook-5-1.cochrane.org\/chapter_9\/9_5_2_identifying_and_measuring_heterogeneity.htm."},{"key":"10.1016\/j.clinthera.2023.11.014_bib0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0022","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0023","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1002\/cncr.33067","article-title":"A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"issue":"10232","key":"10.1016\/j.clinthera.2023.11.014_bib0024","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0025","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0026","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0027","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1158\/1078-0432.CCR-21-2547","article-title":"Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study","volume":"28","author":"Taylor","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0028","doi-asserted-by":"crossref","unstructured":"Nguyen TT, Nhu NT, Tran VK, Nguyen TTH, Lin C-F. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023;15(7):1996. doi:10.3390\/cancers15071996.","DOI":"10.3390\/cancers15071996"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0029","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0030","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0031","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0032","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0033","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0034","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. National Cancer Institute. Accessed November 25, 2023. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.clinthera.2023.11.014_bib0035","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0036","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0037","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"1","author":"Caron","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0038","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0039","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib","volume":"1","author":"Bye","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0040","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3324\/haematol.2015.140558","article-title":"Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib","volume":"101","author":"Lipsky","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2023.11.014_bib0041","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","article-title":"Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer","volume":"6","author":"Gunderson","year":"2016","journal-title":"Cancer Discov"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:24Z","timestamp":1758963624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823004630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0149291823004630"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.11.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}